title: Osteoporosis in women with breast cancer and its effect on quality of life: a pilot study.
abstract: OBJECTIVE
  The primary aim of this study was to evaluate the risk of osteoporosis (OP) in patients who had received adjuvant chemotherapy for breast cancer. The secondary aim was to investigate the effect of OP on the quality of life of these patients.
  
  
  METHODS
  Twenty-six patients with breast cancer and 21 healthy controls were recruited into the study. All breast cancer patients were treated with 6 cycles of adjuvant chemotherapy. Bone mineral density (BMD) was measured by Dual-energy X-ray absorptiometry (DXA). Short Form-36 (SF-36) questionnaire was used to assess the quality of life.
  
  
  RESULTS
  The mean lumbar area BMD value was significantly lower in patients with breast cancer than in healthy controls (p=0.017). There were no significant differences in the femoral area BMD measurements between the groups. OP was more pronounced after 24 months of the last chemotherapy course than in the first 12 months (p=0.04). The most affected domain of the SF-36 in patients with breast cancer was the physical role.
  
  
  CONCLUSIONS
  Adjuvant chemotherapy increases the risk of accelerated bone loss in the lumbar spine. OP should be investigated during follow-up in order to improve the quality of life of the surviving breast cancer patients.
authors: Adnan Menderes University Medical School Hospital, Department of Physical Medicine and Rehabilitation, Aydin, Turkey. dryaseminturan@gmail.com
authors: Y
authors: Y
authors: Turan
authors: Z
authors: Z
authors: Kocaaga
authors: O
authors: O
authors: Karakoyun-Celik
authors: A
authors: A
authors: Gurgan
authors: A
authors: A
authors: Duransoy
mesh_terms: D015502:Absorptiometry, Photon; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D015519:Bone Density / Q000187:drug effects*; D001943:Breast Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging / Q000473:pathology; D008593:Menopause; D008875:Middle Aged; D010024:Osteoporosis / Q000209:etiology*; D010865:Pilot Projects; D011788:Quality of Life
chemical_list: D015251:Epirubicin; D003520:Cyclophosphamide; D005472:Fluorouracil